About Damn Time star, Lizzo, revealed she had lost 16 per cent of her body fat over two years in 2025, but now admits her ...

Shares of Hims and Hers Health (NYSE:HIMS) slid 14% in premarket trading following the telehealth company’s announcement of ...

Facebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...

Despite a significant revenue drop, Medifast Inc (MED) surpasses guidance and focuses on innovative programs to enhance coach productivity and client engagement.

Discover Medifast's Q2 2025 earnings insights, highlighting a business transformation with science-backed health solutions, digital tools, and ...

Shares of Hims & Hers Health fell 13.5% in after-hours trading Monday after the telehealth company missed Wall Street’s ...

Stay updated on Hims & Hers Health Q2 2025 earnings: subscriber growth, global expansion, & personalized care innovation.

Key Points GAAP revenue beat expectations at $105.6 million for Q2 2025 but was down 37.4% year over year. GAAP earnings per share rose to $0.22 for Q2 2025, including a $2.0 million net-of-tax ...

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Once-weekly semaglutide significantly slowed epigenetic aging in adults with HIV-associated lipohypertrophy, as measured by ...